Myostatin (MSTN) is a member of the transforming growth factor-β superfamily of cytokines
and is a negative regulator of skeletal muscle mass. Compared with MSTN+/+ mice, the …

Increasing the size and strength of muscles represents a promising therapeutic strategy for
musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of …

Myostatin deficiency leads in skeletal muscle overgrowth but the precise molecular
mechanisms underlying this hypertrophy are not well understood. In this study, to gain …

▪ Abstract Myostatin is a secreted protein that acts as a negative regulator of skeletal muscle
mass. During embryogenesis, myostatin is expressed by cells in the myotome and in …

See page 1407 A reduction in muscle mass and strength is often observed with aging, and
this phenomenon is known as sarcopenia. This age-related atrophy frequently correlates …

The age-related loss of skeletal muscle (sarcopenia) is a major health concern as it is
associated with physical disability, metabolic impairments, and increased mortality. The …

Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this
transforming growth factor‐β (TGF‐β) superfamily member negatively regulates muscle …

The discovery of myostatin and our introduction to the “Mighty Mouse” over a decade ago
spurred both basic and applied research and impacted popular culture as well. The …

Myostatin, a member of the transforming growth factor-β (TGF-β) superfamily, is a critical
autocrine/paracrine inhibitor of skeletal muscle growth. Since the first observed double …

The lack of myostatin promotes growth of skeletal muscle, and blockade of its activity has
been proposed as a treatment for various muscle-wasting disorders. Here, we have …